Crestline Management, LP Reata Pharmaceuticals Inc Transaction History

Crestline Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$22.15 - $42.11 $103,418 - $196,611	-4,669 Reduced 12.58%	32,439 $1.23 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $201,864 - $379,496	10,400 Added 38.94%	37,108 $933,000
Q2 2022 Aug 12, 2022	BUY	$20.71 - $36.5 $282,090 - $497,166	13,621 Added 104.08%	26,708 $812,000
Q1 2022 May 16, 2022	BUY	$24.12 - $39.6 $315,658 - $518,245	13,087 New	13,087 $429,000
Q4 2021 Feb 14, 2022	SELL	$25.61 - $110.96 $151,329 - $655,662	-5,909 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$100.0 - $143.02 $10,300 - $14,731	-103 Reduced 1.71%	5,909 $594,000
Q2 2021 Aug 13, 2021	BUY	$78.27 - $151.29 $470,559 - $909,555	6,012 New	6,012 $851,000
Q3 2018 Nov 14, 2018	SELL	$35.64 - $92.06 $942,285 - $2.43 Million	-26,439 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$19.94 - $40.96 $1.24 Million - $2.55 Million	-62,236 Reduced 70.18%	26,439 $925,000
Q1 2018 May 15, 2018	BUY	$20.0 - $30.19 $395,380 - $596,826	19,769 Added 28.69%	88,675 $1.82 Million
Q4 2017 Feb 14, 2018	BUY	$22.39 - $33.27 $189,016 - $280,865	8,442 Added 13.96%	68,906 $1.95 Million
Q3 2017 Nov 14, 2017	BUY	$26.29 - $31.88 $1.59 Million - $1.93 Million	60,464	60,464 $1.88 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.